INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

Autor: INOVATYON study group, Colombo, N., Gadducci, A., Sehouli, J., Rulli, E., Mäenpää, J., Sessa, C., Montes, A., Ottevanger, N. B., Berger, R., Vergote, I., D'Incalci, M., Churruca Galaz, C., Chekerov, R., Nyvang, G. B., Riniker, S., Herbertson, R., Fossati, R., Barretina-Ginesta, M. P., Deryal, M., Mirza, M. R., Biagioli, E., Iglesias, M., Funari, G., Romeo, M., Tasca, G., Pardo, B., Tognon, G., Rubio-Pérez, M. J., DeCensi, A., De Giorgi, U., Zola, P., Benedetti Panici, P., Aglietta, M., Arcangeli, V., Zamagni, C., Bologna, A., Westermann, A., Heinzelmann-Schwarz, V., Tsibulak, I., Wimberger, P., Poveda, A.

Publikováno v: British Journal of Cancer, 128, 1503-1513
British Journal of Cancer, 128, 8, pp. 1503-1513

Background This trial investigated the hypothesis that the treatment with trabectedin/PLD (TP) to extend the platinum-free interval (TFIp) can improve overall survival (OS) in patients with recurrent ovarian cancer (OC). Methods Patients with OC (up

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d614c2a7ed8f0a9a0d08a180564fbbf
http://hdl.handle.net/2066/291764

INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

Autor: Colombo, N., Gadducci, A., Sehouli, J., Biagioli, E., Nyvang, G-B., Riniker, S., Montes, A., Ottevanger, N., Zeimet, A. G. G., Vergote, I. B., Funari, G., Baldoni, A., Tognon, G., De Censi, A., Churruca Galaz, C., Chekerov, R., Maenpaa, J., Rulli, E., Fossati, R., Poveda, A.

Publikováno v: Colombo, N, Gadducci, A, Sehouli, J, Biagioli, E, Nyvang, G-B, Riniker, S, Montes, A, Ottevanger, N, Zeimet, A G G, Vergote, I B, Funari, G, Baldoni, A, Tognon, G, De Censi, A, Churruca Galaz, C, Chekerov, R, Maenpaa, J, Rulli, E, Fossati, R & Poveda, A 2020, ' INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line ', Annals of Oncology, vol. 31, no. Suppl. 4, LBA30, pp. S1161 . https://doi.org/10.1016/j.annonc.2020.08.2260

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3062::03bf789d3834a246b705faabb822c34e
https://portal.findresearcher.sdu.dk/da/publications/b7581da9-200a-4387-b5b0-a2496ad4f023

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

268P Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple-negative, EGFR positive breast cancer: A multicenter single arm phase II trial [SAKK 24/14]

Autor: Wicki, A., Mamot, C., Hasler-Strub, U., Riniker, S., Li, Q., Holer, L., Baertschi, D., Zaman, K., von Moos, R., Dedes, K.J., Novak, U., Bodmer, A., Ritschard, R., Obermann, E., Ackermann, C.J., Membrez-Antonioli, V., Zuerrer, U., Caspar, C.B., Rochlitz, C., Winterhalder, R.C.

Publikováno v: In Annals of Oncology September 2021 32 Supplement 5:S479-S479

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.